Jay H. Bream

Jay H. Bream

Auto-generated profile, based on publicly available information

Jay H. Bream

Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2000 in Nature
Verified
Journal Article
Open access
PDF file
Emad El-OmarEmad El-Omar
Emad El-Omar
MCMary Carrington
Mary Carrington
WCWong-Ho Chow
Wong-Ho Chow
KMKenneth E. L. McColl
Kenneth E. L. McColl
JBJay H. Bream
Jay H. Bream
CRCharles S. Rabkin
Charles S. Rabkin
Helicobacter pylori infection is associated with a variety of clinical outcomes including gastric cancer and duodenal ulcer disease1. The reasons for this variation are not clear, but the gastric physiological response is influenced by the severity and anatomical distribution of gastritis induced by H. pylori. Thus, individuals with gastritis predominantly localized to the antrum retain normal (or even high) acid secretion2, whereas individuals with extensive corpus gastritis develop hypochlorhydria and gastric atrophy3, which are presumptive precursors of gastric cancer4. Here we report that interleukin-1 gene cluster polymorphisms suspected of enhancing production of interleukin-1-beta are associated with an increased risk of both hypochlorhydria induced by H. pylori and gastric cancer. Two of these polymorphism are in near-complete linkage disequilibrium and one is a TATA-box polymorphism that markedly affects DNA–protein interactions in vitro. The association with disease may be explained by the biological properties of interleukin-1-beta, which is an important pro-inflammatory cytokine5 and a powerful inhibitor of gastric acid secretion6,7. Host genetic factors that affect interleukin-1-beta may determine why some individuals infected with H. pylori develop gastric cancer while others do not.

11 November 2004 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
WWWendy T. Watford
Wendy T. Watford
BHBruce D. Hissong
Bruce D. Hissong
JBJay H. Bream
Jay H. Bream
YKYuka Kanno
Yuka Kanno
LMLinda Muul
Linda Muul
JOJohn J. O'Shea
John J. O'Shea

20 February 2015 in AIDS
Verified
Journal Article
Closed access
NWNikolas Itaru Wada
Nikolas Itaru Wada
LJLisa P. Jacobson
Lisa P. Jacobson
JMJoseph B. Margolick
Joseph B. Margolick
EBElizabeth Crabb Breen
Elizabeth Crabb Breen
BMBernard Macatangay
Bernard Macatangay
JBJay H. Bream
Jay H. Bream
Objectives: To investigate the impact of HAART-induced HIV suppression on levels of 24 serological biomarkers of inflammation and immune activation. Design: A prospective cohort study. Methods: Biomarkers were measured with multiplex assays in centralized laboratories using stored serum samples contributed by 1697 men during 8903 person-visits in the Multicenter AIDS Cohort Study (MACS) from 1984 to 2009. Using generalized gamma models, we compared biomarker values across three groups, adjusting for possible confounders: HIV-uninfected (NEG); HIV-positive, HAART-naive (NAI); and HAART-exposed with HIV RNA suppressed to less than 50 copies/ml plasma (SUP). We also estimated changes in biomarker levels associated with duration of HIV suppression, using splined generalized gamma regression with a knot at 1 year. Results: Most biomarkers were relatively normalized in the SUP group relative to the NAI group; however, 12 biomarkers in the SUP group were distinct (P < 0.002) from NEG values: CXCL10, C-reactive protein (CRP), sCD14, sTNFR2, tumour necrosis factor-alpha (TNF-α), sCD27, sGP130, interleukin (IL)-8, CCL13, BAFF, GM-CSF and IL-12p70. Thirteen biomarkers exhibited significant changes in the first year after viral suppression, but none changed significantly after that time. Conclusion: Biomarkers of inflammation and immune activation moved towards HIV-negative levels within the first year after HAART-induced HIV suppression. Although several markers of T-cell activation returned to levels present in HIV-negative men, residual immune activation, particularly monocyte/macrophage activation, was present. This residual immune activation may represent a therapeutic target to improve the prognosis of HIV-infected individuals receiving HAART.

17 January 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ZYZhengju Yao
Zhengju Yao
YCYongzhi Cui
Yongzhi Cui
WWWendy T. Watford
Wendy T. Watford
JBJay H. Bream
Jay H. Bream
KYKunihiro Yamaoka
Kunihiro Yamaoka
JOJohn J. O'SHea
John J. O'SHea
Cytokines that use the common gamma chain γc are critical for lymphoid development and function. Mutations of the IL-7 receptor, γc, or its associated kinase, Jak3, are the major cause of human severe combined immunodeficiency. Although activated by IL-7, Stat5a/b (Stat, signal transducer and activator of transcription) have been thought to play limited roles in lymphoid development. However, we now show that mice completely deficient in Stat5a/b have severely impaired lymphoid development and differentiation. Absence of Stat5 also abrogates T cell receptor γ rearrangement and survival of peripheral CD8 + T cells. Thus, deficiency of Stat5 results in severe combined immunodeficiency, similar in many respects to deficiency of IL-7R, γc, and Jak3.

1 May 2003 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
DADavide Agnello
Davide Agnello
CLCarla S. R. Lankford
Carla S. R. Lankford
JBJay Bream
Jay Bream
AMAkio Morinobu
Akio Morinobu
MGMassimo Gadina
Massimo Gadina
DFDavid M. Frucht
David M. Frucht

6 March 2006 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TUTakashi Usui
Takashi Usui
JPJan C. Preiss
Jan C. Preiss
YKYuka Kanno
Yuka Kanno
ZYZheng Ju Yao
Zheng Ju Yao
JBJay H. Bream
Jay H. Bream
WSWarren Strober
Warren Strober
T helper type 1 (Th1) development is facilitated by interrelated changes in key intracellular factors, particularly signal transducer and activator of transcription (STAT)4, T-bet, and GATA-3. Here we show that CD4+ cells from T-bet−/− mice are skewed toward Th2 differentiation by high endogenous GATA-3 levels but exhibit virtually normal Th1 differentiation provided that GATA-3 levels are regulated at an early stage by anti–interleukin (IL)-4 blockade of IL-4 receptor (R) signaling. In addition, under these conditions, Th1 cells from T-bet−/− mice manifest IFNG promotor accessibility as detected by histone acetylation and deoxyribonuclease I hypersensitivity. In related studies, we show that the negative effect of GATA-3 on Th1 differentiation in T-bet−/− cells arises from its ability to suppress STAT4 levels, because if this is prevented by a STAT4-expressing retrovirus, normal Th1 differentiation is observed. Finally, we show that retroviral T-bet expression in developing and established Th2 cells leads to down-regulation of GATA-3 levels. These findings lead to a model of T cell differentiation that holds that naive T cells tend toward Th2 differentiation through induction of GATA-3 and subsequent down-regulation of STAT4/IL-12Rβ2 chain unless GATA-3 levels or function is regulated by T-bet. Thus, the principal function of T-bet in developing Th1 cells is to negatively regulate GATA-3 rather than to positively regulate the IFNG gene.